Review




Structured Review

Agenus Inc gp100 peptide vaccine
Gp100 Peptide Vaccine, supplied by Agenus Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gp100+peptide+vaccine/pm40733649-310-7-13?v=Agenus+Inc
Average 86 stars, based on 1 article reviews
gp100 peptide vaccine - by Bioz Stars, 2026-07
86/100 stars

Images



Similar Products

86
Agenus Inc gp100 peptide vaccine
Gp100 Peptide Vaccine, supplied by Agenus Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gp100+peptide+vaccine/pm40733649-310-7-13?v=Agenus+Inc
Average 86 stars, based on 1 article reviews
gp100 peptide vaccine - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

90
Bristol Myers gp100 peptide vaccine
Clinical outcomes in combination immunotherapy regimens
Gp100 Peptide Vaccine, supplied by Bristol Myers, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gp100+peptide+vaccine/pmc06105674-69-14-23?v=Bristol+Myers
Average 90 stars, based on 1 article reviews
gp100 peptide vaccine - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

90
Vakzine Projekt Management GmbH gp100-peptide-vaccine
Clinical outcomes in combination immunotherapy regimens
Gp100 Peptide Vaccine, supplied by Vakzine Projekt Management GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gp100+peptide+vaccine/10__1055_slash_s___0042___105416-100-1-7?v=Vakzine+Projekt+Management+GmbH
Average 90 stars, based on 1 article reviews
gp100-peptide-vaccine - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

90
Bristol Myers gp100:209-217(210m) & gp100:288(288v) peptide vaccine in incomplete freund’s adjuvant
Clinical outcomes in combination immunotherapy regimens
Gp100:209 217(210m) & Gp100:288(288v) Peptide Vaccine In Incomplete Freund’s Adjuvant, supplied by Bristol Myers, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gp100+peptide+vaccine/pmc04647658-71-47-24?v=Bristol+Myers
Average 90 stars, based on 1 article reviews
gp100:209-217(210m) & gp100:288(288v) peptide vaccine in incomplete freund’s adjuvant - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

90
Bristol Myers gp100 melanoma peptide vaccine
Selected Phase III trials of cancer-specific vaccines
Gp100 Melanoma Peptide Vaccine, supplied by Bristol Myers, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gp100+peptide+vaccine/pmc04918241-21-13-6?v=Bristol+Myers
Average 90 stars, based on 1 article reviews
gp100 melanoma peptide vaccine - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

90
Medarex Inc gp100 peptide vaccine
Selected Phase III trials of cancer-specific vaccines
Gp100 Peptide Vaccine, supplied by Medarex Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/gp100+peptide+vaccine/pm16151408-62-6-9?v=Medarex+Inc
Average 90 stars, based on 1 article reviews
gp100 peptide vaccine - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

Image Search Results


Clinical outcomes in combination immunotherapy regimens

Journal: Experimental & Molecular Medicine

Article Title: Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance

doi: 10.1038/s12276-018-0130-1

Figure Lengend Snippet: Clinical outcomes in combination immunotherapy regimens

Article Snippet: In 2010, a surprising result came from a phase III clinical study of the GP100 peptide vaccine with an anti-CTLA-4 mAb, ipilimumab (MDX-010, Bristol-Myers Squibb).

Techniques:

Selected Phase III trials of cancer-specific vaccines

Journal: Immunotargets and Therapy

Article Title: Therapeutic cancer vaccines and combination immunotherapies involving vaccination

doi: 10.2147/ITT.S40264

Figure Lengend Snippet: Selected Phase III trials of cancer-specific vaccines

Article Snippet: Completed , Peptide , MDX-1379 , Bristol-Myers Squibb, New York, NY, USA , Gp100 melanoma peptide vaccine , Melanoma , NCT00094653 , Median OS with vaccine alone was significantly less than ipilimumab plus vaccine or ipilimumab alone..

Techniques: Adjuvant, Transfection, Plasmid Preparation, Recombinant, Modification, Virus